Monoclonal Antibodies Make Headway in Sjögren Treatment
Positive results were reported from the DAHLIAS study of nipocalimab, the TWINSS study of iscalimab, and a phase 1 trial of tibulizumab, but it was negative news for lusvertikimab.
Medscape Medical News
source https://www.medscape.com/viewarticle/monoclonal-antibodies-make-promising-headway-sj%C3%B6gren-2024a1000ec3?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/monoclonal-antibodies-make-promising-headway-sj%C3%B6gren-2024a1000ec3?src=rss
Comments
Post a Comment